Appendix Table C21. KQ1 Outcome II. Transfusion subgroup analysis: Epoetin versus control

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Study** | **Subgroups prospectively** **stratified for**  | **Epo n/N (%)** | **Control n/N (%)** | **p-value** | **Comments** |
| Razzouk 2004 | All patients | 72/111 (35%) | 85/111 (23%) | p=0.0536 | p value refers to proportion NOT transfused |
| ALL (n=75) | 26/40 (65.0%) | 22/35 (62.9%) |  |  |
| **Witzig 2004Aapro 2008** | All patients | 42/166 (25.3%)63/232 (27.0%) | 65/164 (39.6%)33/231 (14.0%) | p=0.005 |  |
| mild anemia (Baseline Hb > 9<11 g/dL)  | 19%20/ 232 (8.6%) | 29%39/231 (16.9%) |  |  |
| severe anemia (Basline Hb < 9>11 g/dL)  | 40% | 62%  |  |  |
| **Chang 2005** | All patients | 15/175 (8.6%) | 40/175 (22.9%) | p<0.0001 |  |
| Adjuvant | 10/175 (7.2%) | 30/175 (22.1%) | NR |  |
| Metastatic | 5/175 (14.7%) | 10/175 (26.3%) | NR |  |
| Baseline Hb <11 g/dL | 11/175 (20.4%) | 20/175 (38.5%) | NR |  |
| Baseline HB≥11 g/dL | 4/175 (3.4%) | 20/175 (16.4%) | NR |  |
| **Hernandez 2009** | Study period | 22/99 (22.2%) | 48/116 (41.4%) | p=0.008 |  |
| First 4 wks excluded | 58/193 (30.1%) | 91/193 (47.2%) | p=0.003 |  |
| Per protocol analysis set, first 4 wks excluded | 44/181 (24.3%) | 76/185 (41.1%) | p<0.001 | To account for protocol deviations, the primary endpoint was also examined using an alternate analysis set (per-protocol analysis set) |
| **Savonije 2005** | Study period | 77/211 (36%) | 66 /102 (65%) | p<0.001 |  |
| First 4 wks excluded | 49/211 (23%) | 53/102 (52%) | p<0.001 |  |
| **Tsuboi 2009** | Study period | 7/61 (11.5%) | 7/56 (12.5%) | p=0.856 |  |
| First 4 wks excluded | 5/61 (8.2%) | 7/56 (12.5%) | p=0.443 |  |
| **Witzig 2005** | All patients | 42/166 (25.3%) | 65/164 (39.6%) | p=0.005 |  |
| mild anemia (Hb > 9 g/dL)  | 32/166 (19.2%) | 48/164 (29.3%) | NR | Numbers derived from percentages 19% and 29% respectively |
| severe anemia (Hb < 9 g/dL)  | 66/166 (39.8%) | 102/164 (62.2%)  | NR | Numbers derived from percentages 40% and 62% respectively |
| **Witzig 2005** | All patients | 39/154 (25.3%) | 60/151 (39.7%) | NR |  |
| Baseline serum Epo level low (<44 U/ml) | 8/44 (18.2%) | 18/57 (31.6%) | NR |  |
| Baseline serum Epo level mid (44-86 U/ml) | 14/56 (25.0%) | 19/47 (40.4%) | NR |  |
| Baseline serum Epo level high (>86 U/ml) | 17/54 (31.5%`) | 23/47 (48.9%) | NR |  |